BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) said that the United States Patent and Trademark Office (USPTO) has approved a patent for its primary cancer treatment, BVX001.
The patent, numbered US11,732,040, is part of the broader "therapy" patent family, which is currently under review in eight countries globally. This patent offers protection for BVX001, which targets specific markers on cancer cells.
In the US, the patent safeguards a treatment that uses antibodies combined with a substance that can kill cancer cells.
BiVictriX's treatment is designed to bind to unique Bi-Cygni twin markers, known as CD7 x CD33.
It is primarily aimed at treating acute myeloid leukaemia (AML), but the patent covers any blood cancer that shows the CD7 and CD33 markers.
This means that even if other companies try to develop similar treatments using different methods, BiVictriX's patent offers them a strong commercial position.
In addition to the US patent, BiVictriX has received a notice of allowance from the Japanese Patent Office for related protection. Sign-off is expected to be approved soon, adding another layer of protection for BVX001.
BiVictriX is also awaiting patent approvals in six other countries, with more expected in the upcoming months.
Chief executive Tiffany Thorn said: "I am excited to announce that our first patent has been granted in the United States.
"This patent relates to our broadest patent family, providing robust protection for BVX001 at the antigen level, across multiple cancer types, and acts as a key milestone for the company demonstrating the breadth of patent protection we can achieve with the Bi-Cygni approach.
"This patent grant is expected to be the first of many as we continue to prosecute the wider patent family in seven further jurisdictions worldwide, creating a robust patent-protected portfolio."